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BACKGROUND: The optimal treatment of desmoid tumours is controversial. We evaluated desmoid management in Dutch familial
adenomatous polyposis (FAP) patients.
METHODS: Seventy-eight FAP patients with desmoids were identified from the Dutch Polyposis Registry. Data on desmoid
morphology, management, and outcome were analysed retrospectively. Progression-free survival (PFS) rates and final outcome were
compared for surgical vs non-surgical treatment, for intra-abdominal and extra-abdominal desmoids separately. Also, pharmacological
treatment was evaluated for all desmoids.
RESULTS: Median follow-up was 8 years. For intra-abdominal desmoids (n¼62), PFS rates at 10 years of follow-up were comparable
after surgical and non-surgical treatment (33% and 49%, respectively, P¼0.163). None of these desmoids could be removed entirely.
Eventually, one fifth died from desmoid disease. Most extra-abdominal and abdominal wall desmoids were treated surgically with a
PFS rate of 63% and no deaths from desmoid disease. Comparison between NSAID and anti-estrogen treatment showed
comparable outcomes. Four of the 10 patients who received chemotherapy had stabilisation of tumour growth, all after doxorubicin
combination therapy.
CONCLUSION: For intra-abdominal desmoids, a conservative approach and surgery showed comparable outcomes. For extra-
abdominal and abdominal wall desmoids, surgery seemed appropriate. Different pharmacological therapies showed comparable
outcomes. If chemotherapy was given for progressively growing intra-abdominal desmoids, most favourable outcomes occurred
after combinations including doxorubicin.
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Familial adenomatous polyposis (FAP) is a dominantly inherited
cancer predisposition syndrome, caused by mutations in the
adenomatous polyposis coli (APC) gene. Carriers of the mutated
APC gene develop hundreds to thousands of adenomatous polyps
in the colon and rectum, leading to a nearly 100% cancer risk
by the age of 40 years (Lynch et al, 2008). By performing a
prophylactic colectomy, the risk of death due to colorectal cancer
is decreased. Among FAP patients, a spectrum of extra-colonic
manifestations is often observed, including duodenal cancer
and desmoid tumours. These manifestations are currently the
most common causes of death after colorectal cancer (Arvanitis
et al, 1990).
Desmoid tumours or aggressive fibromatoses are histologically
benign proliferations of fibro-aponeurotic tissue (Goldblum
and Fletcher, 2002). In the general population, the incidence of
desmoids is about 3 per million per year, and the tumours are
mainly located in the extremities or in the abdominal wall (Fallen
et al, 2006). Of all patients presenting with a desmoid tumour,
at least 7.5% has FAP or will develop FAP later in life
(Nieuwenhuis et al, 2010, submitted for publication). In the total
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and are usually located in the mesentery of the small bowel
(Fallen et al, 2006). Desmoids range from small, indolent,
or even regressive tumours to large and progressive growing
neoplasms causing obstruction of vital organs. Desmoid tumours
do not metastasise, although they can present as multifocal
disease.
Treatment of FAP-related desmoid tumours is contro-
versial (Sleijfer, 2009). As desmoid tumours are rare, and show a
variable disease course, the effectiveness of treatment is
difficult to determine. There are no randomised controlled trials.
Usually, extra-abdominal and abdominal wall desmoid tumours
are removed surgically, but two recently published reports
argued a wait-and-see policy for patients in which surgery would
result in major functional or cosmetic defects (Bonvalot et al,
2008; Stoeckle et al, 2009). For intra-abdominal desmoid tumours,
surgery is not recommended because surgical resection is
complicated or impossible in most cases, and because of high
recurrence rates (Rodriguez-Bigas et al, 1994). Furthermore,
there is evidence that tissue damage is a risk factor for desmoid
development (Clark et al, 1999; Bertario et al, 2001). The most
frequently used pharmacological therapies include non-steroidal
anti-inflammatory drugs (NSAIDs), hormonal agents, biological
agents, and cytotoxic chemotherapy (Janinis et al, 2003;
Tolan et al, 2007). Currently, most guidelines recommend a
stepwise approach, starting with NSAIDs (preferably sulindac).
If this is not effective, hormonal therapy is added, most
commonly consisting of tamoxifen or toremifene. Fast growing
desmoid tumours not responsive to these agents are treated by
cytotoxic chemotherapy or surgery (http://www.nccn.org; Janinis
et al, 2003; Latchford et al, 2006; Melis et al, 2008; Casali and
Blay, 2010).
In the present study, we retrospectively evaluated long-term
outcome of Dutch FAP patients with desmoid tumours, under-
going surgical, and pharmacological therapies. First, we assessed
the effectiveness of surgical vs non-surgical strategies for intra-
and extra-abdominal desmoid tumours, and second, we assessed
the effectiveness of various pharmacological modalities in desmoid
tumour treatment.
MATERIALS AND METHODS
Patients
The FAP database of the Netherlands Foundation for the Detection
of Hereditary Tumours was used for the study. This national
database comprises medical data on over a thousand FAP patients.
Patients gave written consent to register their personal and
medical information. A total of 78 patients with desmoid tumours
were identified. Patient characteristics, genetic data, and medical
information were retrieved from the database. The study was
approved by the Medical Ethics Committee.
Desmoid localisation was defined as ‘at least intra-abdominal’ or
‘extra-abdominal and in the abdominal wall’. For all patients,
the type of primary therapy for the first desmoid tumour was
determined. If surgery was performed due to the severity of
desmoid symptoms or with the aim of removing the desmoid
tumour, patients were categorised into the ‘surgery’ group. All
patients who received conservative treatment (wait-and-see or
medication), and patients whose desmoid tumour was detected
coincidentally during another surgical procedure, without resec-
tion, were categorised into the ‘non-surgery’ group.
Time from diagnosis of the desmoid tumour to progression of
desmoid tumour growth was calculated. Progression of desmoid
tumour growth was defined as tumour growth causing clinical
symptoms. Also, for each patient, the status of desmoid growth at
the end of follow-up was assessed and categorised into either
‘regression or stabilisation of tumour growth’ or ‘progression of
tumour growth’.
Data analysis
Baseline characteristics between the groups were analysed by
univariate analysis (Student’s t-test for numerical variables, w
2-test
for categorical variables). Progression-free survival (PFS) was
calculated by the Kaplan–Meier method. Univariate analysis was
performed using the log-rank test. Statistical analyses were
performed using the Statistical Package for Social Sciences (SPSS)
version 16.0 (Chicago, IL, USA).
RESULTS
Group description
Between January 1978 and January 2010, 78 FAP (34 males)
patients had developed at least one desmoid tumour. Desmoid
localisations were as follows: 49 (62.8%) intra-abdominal,
13 (16.7%) involving both the mesentery and the abdominal wall,
13 (16.7%) abdominal wall only, 2 (2.6%) trunk, and 1 (1.3%)
head/neck. The median size of the desmoids was 7cm, ranging
from 1 to 24cm. Fifty-six patients were treated at a tertiary referral
centre, 22 in a local hospital. The median follow-up period from
diagnosis of desmoid to the last observation was 8 years, ranging
from 0 to 29 years (Table 1).
Table 1 Characteristics and follow-up data of FAP-related mesenterial
desmoid tumours, according to primary surgical treatment vs non-surgical
treatment
Primary treatment
Surgery
(N¼36)
No surgery
(N¼26) P-value
Sex, male
N (%) 16 (44) 13 (50) 0.665
Age at first DT (years)
Median, min–max 30, 15–54 35, 14–51 0.396
Size first DT (cm)
Median, min–max 9.5, 1–20 6.5, 2–24 0.568
DT progression, N (%) 26 (72) 13 (50) 0.074
Time to first DT progression (months)
Median, min–max 13, 1–189 24, 2–229 0.913
Total follow-up from diagnosis of
first DT to last observation (years)
Median, min–max 8, 0–29 7, 0–28 0.762
Age at last follow-up (years)
Median, min–max 41, 23–67 42.5, 18–79 0.606
Status at last follow-up, N (%)
Alive 21 (58) 18 (69) 0.783
Lost to follow-up 1 (3) 1 (4)
Dead due to DT 9 (25) 5 (19)
Dead due to other cause 5 (14) 2 (8)
DT status at last follow-up, N (%)
Regression/stable 25 (69) 20 (77) 0.515
Progression/variable 11 (31) 6 (23)
Abbreviations: DT¼desmoid tumour; FAP¼familial adenomatous polyposis.
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desmoid tumours
The group with ‘at least intra-abdominal’ desmoid tumours
consisted of 62 patients. In 36 patients, primary treatment
consisted of surgery with the intention to remove the intra-
abdominal desmoid tumour. Twelve of these patients received
desmoid-targeted medication immediately after surgery. Primary
treatment was non-surgical in 26 patients (17 wait-and-see policy
and 9 medication). The surgery and non-surgery groups
were comparable for sex, age at first desmoid, size of first desmoid
tumour, and duration of follow-up (Table 1). None of the
intra-abdominal desmoid tumours could be resected entirely.
The probability of PFS for the surgery group was 63.9%, 43.8%,
and 32.9% after 1, 5 and 10 years, respectively. In the non-surgical
group, these percentages were 80.8%, 55.3%, and 49.1%, respec-
tively (log-rank, P¼0.163) (Figure 1).
When considering desmoid status at the last observation, the
majority of desmoid tumours had become stable or regressive
in both the surgery and non-surgery groups (69% and 77%,
respectively, P¼0.515). In the surgery and non-surgery groups,
25% and 19%, respectively, died from desmoid disease (P¼0.783)
(Table 1).
Extra-abdominal and abdominal wall desmoid tumours
Sixteen patients had extra-abdominal desmoid tumours (Table 2).
Thirteen patients had a desmoid tumour in the abdominal wall
(3 male patients and 10 female patients), two male patients had
desmoids at the thoracic wall and back, and one female patient had
a desmoid tumour localised in the muscles of the neck. Fourteen
(87.5%) of the tumours were treated surgically, with seven R1/2
(microscopically/macroscopically irradical), six Rx (unknown
surgical margin), and one R0 (radical) excision. One, 5, and
10 years after primary surgery, 93.3%, 71.1%, and 63.2% of
patients were free of progression. In most patients, progression
was observed within 6 years after primary surgery (Figure 2). None
of the patients died from desmoid disease. When considering
desmoid status at the last observation, three quarter of the
desmoid tumours had stabilised or regressed.
Effectiveness of pharmacological treatment
Various pharmacological agents were used, including NSAIDs
(sulindac and celecoxib) and hormonal medications (tamoxifen,
toremifene, LHRH-agonists, and anastrozole). For all patients
who received medical treatment as primary therapy, irrespective of
previous surgery, survival rates were calculated. After 5 years of
follow-up, the PFS rates were similar after treatment with NSAIDs
and hormonal medications including combination therapy, as
shown in Figure 3 (log-rank, P¼0.111). A small subset of patients
had received other drugs, including prednisone, interferon, and
colchicines. After these medications, both positive as well as
negative effects on desmoid tumour growth were reported, but
patient numbers were too small to perform statistical analysis.
Cytotoxic chemotherapy and imatinib
Ten patients received cytotoxic chemotherapy, and three patients
had treatment with imatinib. Effects and complications of these
therapies are summarised in Table 3. The most frequently used
chemotherapy was doxorubicin, in combination with other agents
such as DTIC, carboplatin, and ifosfamide. Effects of chemo-
therapy were variable. Four patients eventually had regression or
stabilisation of tumour growth, and five patients had progression
of tumour growth. One patient died only a few days after the first
session of chemotherapy due to a massive pulmonary embolism,
caused by pressure of the desmoid tumour on the large veins.
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Figure 1 Progression-free interval after primary surgical (black line)
and non-surgical (grey line) treatment for mesenterial desmoid tumours in
FAP patients (log-rank test, P¼0.163).
Table 2 Characteristics and follow-up data of extra-abdominal and
abdominal wall desmoid tumours
Extra-abdominal and
abdominal wall DT (N¼16)
Sex, male, N (%) 5 (31)
DT localisation, N (%)
Abdominal wall 13 (81)
Trunk 2 (13)
Head/neck 1 (6)
Age at first DT (years)
Median, min–max 30.5, 8–57
Size of first DT (cm)
Median, min–max 5, 2–13
Primary treatment, N (%)
Surgery 13 (81)
Surgery and medication 1 (6)
Medication 1 (6)
Wait-and-see 1 (6)
DT progression, N (%) 5 (31)
Time to DT growth months
Median, min–max 30 (2–73)
Status last follow-up, N (%)
Alive 13 (81)
Dead due to DT 0
Dead due to other cause 3 (19)
Desmoid status at last follow-up, N (%)
Regression/stable 12 (75)
Progression/variable 4 (25)
Abbreviation: DT¼desmoid tumour.
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chemotherapy. Furthermore, three patients developed severe
complications as fistulas and abscesses (after 5, 18, and 60 months,
respectively) besides the known spectrum of side effects associated
with cytotoxic chemotherapy.
In the three patients receiving imatinib (of which two also had
received chemotherapy), variable outcomes were seen, but the
follow-up intervals were limited.
Radiotherapy and embolisation
A total of five patients were treated by radiation therapy. Three
patients had radiation therapy for intra-abdominal desmoids. In
one of them, the tumour size decreased, enabling surgery. The two
other patients had stable desmoids during 6 years and progression
within 1 year, respectively. Two patients had radiation therapy for
extra-abdominal desmoid tumours: a patient with trunk desmoids
had progression within a few months, and another patient had
regression of an abdominal wall desmoid after irradiation;
however, this patient developed serious radiation enteritis.
In two patients, the desmoid tumours were treated by
embolisation. However, in both patients this treatment failed as
the desmoids did not have large supplying vessels.
DISCUSSION
The present study demonstrates that for intra-abdominal desmoid
tumours, similar PFS rates were observed after surgical treatment
and a more conservative approach. None of the intra-abdominal
desmoids could radically be resected by surgery, but at the end of
the follow-up period, two thirds of the intra-abdominal desmoids
showed regression or stabilisation of tumour growth. About one
fifth of the patients died due to complications of an intra-
abdominal desmoid tumour. Most patients with abdominal wall
and extra-abdominal desmoid tumours were treated surgically.
The PFS rates were greater than after surgery of intra-abdominal
desmoids, and at the end of the follow-up period, in 75% of the
patients the tumours had stabilised or decreased in growth. None
of these patients died from desmoid disease. Evaluation of
pharmacological agents showed comparable PFS probabilities
after NSAIDs and hormonal agents including combination of both
medicines. Effects of chemotherapy were variable, with doxor-
ubicin-based regimens being most effective.
The optimal treatment of intra-abdominal desmoids is un-
known. Previous studies reported high recurrence rates after
surgery and a low success rate of radical removal of desmoid
tumours (Rodriguez-Bigas et al, 1994; Heiskanen and Ja ¨rvinen,
1996). On the other hand, favourable outcomes have been reported
after surgery performed by experienced surgeons in carefully
selected patients (Latchford et al, 2006). In our series, none of the
desmoids could be radically resected and the PFS was similar after
surgery compared to conservative treatment. Based on these
findings, a conservative approach appears to be the preferred
choice in patients with large stable or slowly growing desmoids.
Only in cases of progressively growing desmoids, with complica-
tions such as obstruction of the small bowel, surgical treatment
might be an option. In such patients, minimal surgery (intestinal
bypass) could be performed. In patients with obstruction of the
ureter, stenting of the ureter might be indicated. These conclusions
support the current guidelines on the treatment of desmoid
tumours (http://www.nccn.org) (Casali and Blay, 2010).
Extra-abdominal and abdominal wall desmoid tumours are
generally more suitable for surgical therapy than mesentery
desmoids. Previous studies reported mainly good outcomes after
surgery, although recurrence was common after excision (Clark
et al, 1999; Melis et al, 2008). Recent reports proposed a wait-
and-see policy for patients in which major surgical defects are
expected, because spontaneous regression or tumour stabilisation
is not uncommon (Bonvalot et al, 2008; Fiore et al, 2009; Stoeckle
et al, 2009). In our series, the majority of extra-abdominal and
abdominal wall desmoids was resected, with overall favourable
outcomes, despite only few radical resections. Based on this and
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abdominal wall desmoid tumours. In patients in which surgery
would result in serious defects, a wait-and-see strategy should be
considered.
Commonly used pharmacological agents are NSAIDs and
hormonal agents. One systematic review showed favourable
outcomes after using NSAIDs and hormonal agents, although the
results might be confounded by successful case reports (Janinis
et al, 2003). Another prospective study showed the effectiveness of
high-dose tamoxifen (120mg) and sulindac (300mg) in 9 out of
13 patients (69%), compared to stabilisation after surgery and
medication in only 1 out of 4 patients (25%) after 10 years of
follow-up (Hansmann et al, 2004). Based on these results, the
authors advised high-dose tamoxifen and sulindac as the primary
treatment for FAP-related desmoid tumours. Recently, another
retrospective study reported effective hormonal therapy for
desmoid tumours (De Camargo et al, 2010). Our study showed
no significant differences in PFS rates between NSAIDs and
hormonal treatment including a combination of both medicines.
The PFS was about 50% at 5 years of follow-up. However, patients
in our study received various doses of hormonal agents. Possibly,
hormonal treatment at higher doses would have led to significant
better outcomes. Based on personal experience from our authors
(H.G.), the optimal dose of tamoxifen is 40mg 4 times a day, and
for toremifene 60mg 4 times a day. Based on this and previous
studies, treatment with NSAIDs and/or hormonal agents seems to
be the best option for large and/or progressive desmoids.
Recently, several studies reported successful treatment of
desmoids with pegylated liposomal doxorubicin, with acceptable
side effects (Gega et al, 2006; Bertagnolli et al, 2008; Constanti-
nidou et al, 2009; De Camargo et al, 2010). All four patients in our
study who reached stabilisation or regression after chemotherapy
were treated with doxorubicin. Our findings and those of others
suggest that (pegylated liposomal) doxorubicin-based chemo-
therapeutic regimens are effective for patients with progressive,
symptomatic desmoid tumours. Inspite of previous promising
reports (Heinrich et al, 2006; Wcisio et al, 2007), imatinib
treatment had no evident positive effects in our patients. Long-
term effects of targeted therapies are yet to be evaluated. Recently,
a study to evaluate imatinib in desmoid tumours was initiated
(NCT01137916).
In the past, radiotherapy alone or in combination with surgery
was shown to be effective in sporadic, mainly extra-abdominal
desmoid tumours (Ballo et al, 1999; Nuyttens et al, 2000; Lev et al,
2007; Guadagnolo et al, 2008). Radiotherapy enabled surgery in
one of our patients, but in other patients disease progression after
radiotherapy was observed. Recently, an EORTC study (EORTC-
62991, EORTC-22998, and NCT00030680) was performed to
evaluate moderate dose radiotherapy for inoperable desmoid
tumours. Results of this study are not yet available. According to
the American National Comprehensive Cancer Network guidelines,
radiotherapy should be considered only in desmoid tumours
located at the extremities (http://www.nccn.org). Embolisation
showed not to be a reliable option for desmoid treatment.
Table 3 Description of treatment outcome of patients who received cytotoxic chemotherapy and/or targeted agents as desmoid treatment
Sex Site DT
Age
(years) Treatment Effect on desmoid growth
Follow-up
(months)
Male Mesentery 45 Irresectable DT, etoposide and ifosfamide,
tamoxifen tamoxifen and LHRH-agonist
anastrozole
Quick regression DT, necrosis in DT
Stabilisation, after 5 years progression
Progression
5
70
5
Male Head, abd. wall and
mesentery
15–17 R2 resection DT head, RT mes. DT, sulindac,
toremifene doxorubicine and DTIC, R2
resection mes. DT sulindac, toremifene, R2
resection abd. wall DT all medication stopped
Progression mes. DT
Stabilisation, after 2 years abd. wall DT
Both periods of progression and regression, after 2
years growth DT head, DT mes. and abd. wall stable
Stabilisation
35
38
100
36
Male Mesentery 29 R2 resection, sulindac, toremifene doxorubicine
and carboplatin R2 resection, sulindac,
tamoxifen
Progression
Regression o25%
Stabilisation
11
7
50
Male Mesentery 29 R2 resection, sulindac, tamoxifen, toremifene
doxorubicine and ifosfamide, sulindac,
toremifene imatinib
Progression
Stabilisation, after 8 months progression
Stabilisation, but fistulas and abscesses at DT
38
8
10
Female Abd. wall, trunk,
breasts, neck
25–40 Multiple R2 resections, tamoxifen, sulindac,
LHRH-agonists, anastrozole, radiotherapy
imatinib
Progression and multiple new DT
Progression
Progression
11
10
Male Mesentery 32 R2 resection doxorubicine and DTIC Progression 19
Regression, death not due to DT 184
Male Mesentery 30 Chemotherapy
a and radiotherapy, R2 resection
colchicine, LHRH-agonists, anti-estrogens,
prednison, IFN
Stabilisation for 4 years
Progression; after colchicine multiple abscesses;
death due to DT
51
58
Female Mesentery and abd.
wall
24 Naproxen, toremifene doxorubicine and DTIC Progression
Progression, death due to DT
16
3
Female Mesentery 33–35 Sulindac, anti-estrogens, DT irresectable
liposomal doxorubicine
Progression
Death pulmonary embolism, due to compression
of DT on the large veins
24
0
Female Mesentery 35–37 Wait-and-see, sulindac, celecoxib, tamoxifen,
toremifene carboplatin and doxorubicine
imatinib fulvestrant
Progression
Necrosis in DT, fistulas and abscesses
Stabilisation, after 1 year progression
Stabilisation, after 2 years progression and death
due to DT
37
7
12
19
Male Mesentery 47 Irresectable DT, sulindac, tamoxifen vinblastin
and methotrexat
Progression
Progression, death due to desmoid
4
18
Abbreviations: abd. wall¼abdominal wall; DT¼desmoid tumour; DTIC, dacarbazine; IFN¼interferon; LHRH, luteinizing hormone releasing hormone; Mes.¼mesenterial;
RT¼radiotherapy.
aDetails and type of chemotherapy are not available.
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treatment of desmoid tumours in FAP patients. Nationwide data,
both from university hospitals as well as local hospitals were
included, thus avoiding potential confounding by patient selection.
However, because of the retrospective study design, we were not
able to gain information about the selection of patients for certain
treatment modalities. Nevertheless, this is a complete and
informative series on desmoid treatment to date. For future
studies, a prospective, randomised study design would be a more
robust approach to this research question.
For clinical practice, we recommend surgery for patients with
extra-abdominal and abdominal wall desmoid tumours, unless
major surgical defects are expected. For patients with stable intra-
abdominal desmoid tumours, both a wait-and-see strategy as well
as pharmacological treatment are appropriate. Cytotoxic chemo-
therapy may be effective in patients with progressively growing
desmoids. In the case of severe complications, including ileus,
perforations, and abscesses, surgery is indicated.
In conclusion, desmoid disease is a heterogeneous disease
entity, with various treatment modalities. Clustering of desmoid
patients in some specialised referral centres will benefit treatment
and follow-up, and enables further research into this controversial
topic.
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